Table 1:
Baseline Characteristics | Exposed to Nevirapine N=205 | Non Exposed to Nevirapine N=84 | Total N=289 |
P-value |
---|---|---|---|---|
Age years: median (IQR) | 28.5(26–32) | 30(28–34) | 29(26–33) | 0.005 |
Baseline CD4+ cells/mm3: median (IQR) | 175.5(128–198) | 175.5(106–208) | 175.5(124–208) | 0.56 |
Type of ART regimen initiated: n (%) | ||||
Started on NVP based regimen | 197(96.1) | 83(98.8) | 280(96.9) | 0.23 |
Started on EFV based regimen | 8(3.8) | 1(1.2) | 9(3.1) | |
WHO stage: n (%) | ||||
1 | 42(20.5) | 14(16.7) | 56(19.4) | 0.009 |
2 | 100(48.8) | 32(38.0) | 132(45.7) | |
3 | 55(26.8) | 26(31) | 81(28.0) | |
4 | 8(3.9) | 12(14.3) | 20(6.9) | |
Disclosure status to partner (n=286) : n (%) | ||||
Yes | 137(66.8) | 54(66.7) | 191(66.8) | 0.98 |
No | 68(33.2) | 27(33.3) | 95(33.2) | |
Duration spent in school (years): median (IQR) | 8(6–11) | 9(6–11) | 8(6–11) | 0.57 |
Parity (number of pregnancies) at enrolment: median (IQR) years | 3 (2–5) | 3(2–5) | 3(2–5) | 0.62 |
Marital status (n=286): n (%) | ||||
Married | 115(56.1) | 47(58.0) | 162(56.5) | |
Not married | 90(43.9) | 34(42) | 125(43.5) | 0.77 |
Duration since last NVP exposure to initiation of treatment (months): median (IQR) | 28(9.0–56.8) |
IQR: interquartile range